Company: GAUZ
Filing Date: 2025-12-03
Form Type: 6-K
Source: 0001213900-25-117829
Chunk: 0

Company: Gauzy Ltd.
Filing Date: 2025-12-03
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of December 2025

Commission file number: 001-42124

GAUZY LTD.

(Translation of registrant’s name into English)

14 Hathiya Street

Tel Aviv, Israel

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

Funding Transactions

On December 2, 2025, Gauzy (the “Company”)
announced that it has raised a $12 million investment in new cash in privately negotiated transactions with existing investors and stakeholders
to advance the operational objectives of the Company and its subsidiaries.

The funding transactions were initially structured
in a manner whereby the Company received an advance of $11 million in funds in exchange for the entry into Share Issuance Agreements with
certain investors including Chutzpah Holdings and other stakeholders (the “Share Issuance Agreements”) whereby
the Company committed to, within twenty-one (21) days from the date of the relevant agreement or such later date as decided by the investor
in its sole discretion (such date, the “Issuance Date”), either (1) issue ordinary shares (or
pre-funded warrants) to the investors at a price equal to 70% of the official closing price of the Company’s ordinary shares as
reported on Nasdaq Stock Market (“Nasdaq”) for the trading day immediately prior to the applicable Issuance
Date or the date of the relevant agreement, whichever is lesser (such price, the “Reference Price”); or (2)
enter into a convertible loan agreement with the investors on terms acceptable to the investors in their reasonable discretion (the “Convertible Loan”).

Additionally, in the event that Company issues
ordinary shares to the investors on the Issuance Date, the Company further agreed to issue to the investors warrants to purchase 100%
of the ordinary shares issued to the investors on the Issuance Date with an exercise price equal to 125% of the Reference Price.